# The Objective of This Study is to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm.

> **NCT03641950** · PHASE4 · COMPLETED · sponsor: **Hugel** · enrollment: 249 (actual)

## Conditions studied

- Essential Blepharospasm

## Interventions

- **DRUG:** Botulinum toxin type A

## Key facts

- **NCT ID:** NCT03641950
- **Lead sponsor:** Hugel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-30
- **Primary completion:** 2015-05
- **Final completion:** 2016-01-07
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2018-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03641950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03641950, "The Objective of This Study is to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03641950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*